Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies

Abstract

A common strategy to target nanoparticles to tumours is conjugation with specific antibodies, targeting protein expressed preferentially by cancer cells. Here the authors show that the number of antibodies bound to the nanoparticle influences the targeting abilityin vitro and in vivo.